JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Cells / Cell Lines

BCMA CHO Recombinant Cell Line (High Expression)

SKU : BHC18200288

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	79500-H
Description	Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. Mycoplasma testing: This cell line has been screened using the MycoAlert Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control. Host Species: hamster Supplied as Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS
Background	B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. CART-BCMA is an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR (chimeric antigen receptor). CAR T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.
Host Cell	CHO
Species	Human
Synonyms	tumor necrosis factor receptor superfamily member 17, TNFRSF17
Shipping Temperature	-80°C (dry ice)
Note	License Disclosure: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid freeze/thaw cycles.

Storage Stability	Immediately upon receipt, store vials in liquid nitrogen

Reference	1. Ghosh A, et al. CAR T cell therapy for multiple myeloma Leuk Lymphoma. 2017 Nov; 6:1-12.2. Sanchez E, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018 Mar; 7:1-11.3. Sohail A., et al. Emerging immune targets for the treatment of multiple myeloma. Immunotherapy. 2018 Feb 1; 10(4):265-282.4. Sidaway P., et al. Anti-BCMA CAR T cells show promise in MM. Nat Rev Clin Oncol. 2016 Sep;13(9):530.

Product Manual	Datasheet

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHC18200288	79500-H	2 vials	$7150		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.